Morningstar Investment Management LLC Reduces Holdings in Illumina, Inc. $ILMN

Morningstar Investment Management LLC lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 24.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 22,538 shares of the life sciences company’s stock after selling 7,355 shares during the quarter. Morningstar Investment Management LLC’s holdings in Illumina were worth $2,956,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Hantz Financial Services Inc. lifted its position in shares of Illumina by 100.6% during the 4th quarter. Hantz Financial Services Inc. now owns 7,087 shares of the life sciences company’s stock valued at $930,000 after buying an additional 3,554 shares during the last quarter. Praxis Capital Management LLC purchased a new position in shares of Illumina during the 4th quarter valued at $393,000. North Star Asset Management Inc. lifted its position in shares of Illumina by 26.3% during the 4th quarter. North Star Asset Management Inc. now owns 183,697 shares of the life sciences company’s stock valued at $24,094,000 after buying an additional 38,220 shares during the last quarter. Prospera Financial Services Inc lifted its position in shares of Illumina by 26.2% during the 4th quarter. Prospera Financial Services Inc now owns 6,608 shares of the life sciences company’s stock valued at $867,000 after buying an additional 1,371 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Illumina by 40.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,977 shares of the life sciences company’s stock valued at $784,000 after buying an additional 1,710 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $144.41 on Monday. The business’s 50-day moving average price is $130.45 and its two-hundred day moving average price is $130.99. Illumina, Inc. has a twelve month low of $78.55 and a twelve month high of $155.53. The stock has a market cap of $21.85 billion, a P/E ratio of 26.26, a PEG ratio of 2.39 and a beta of 1.42. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Robert W. Baird set a $137.00 price target on Illumina in a research report on Friday, February 6th. Guggenheim increased their price objective on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Piper Sandler dropped their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. JPMorgan Chase & Co. increased their price objective on Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Finally, Citigroup increased their price objective on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $137.75.

Insider Activity

In other news, Director Keith A. Meister sold 225,067 shares of the stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the transaction, the director directly owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. This represents a 5.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 330,160 shares of company stock worth $48,028,308 over the last quarter. Corporate insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.